Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rexulti

- PMLiVE

Otsuka expands CNS presence with Avanir purchase

Deal for US biotech is valued at $3.5bn

- PMLiVE

NICE backs drug to cut alcohol consumption

Final guidance for Lundbeck’s Selincro for use on NHS in England

- PMLiVE

Lundbeck CEO resigns after rule breach

Ulf Wiinberg accepted gift of shares in Stratified Medical

- PMLiVE

Lundbeck still feeling effects from Cipralex patent loss

The antidepressant sales dropped another 33% in the third quarter

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Lundbeck launches Brintellix in first EU market

The antidepressant set to sell worldwide

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

- PMLiVE

Otsuka launches European ADPKD forum

Aims to lead awareness raising plans for rare genetic condition

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links